New way to halt leukemia relapse shown promising in mice
(Hiroshima University) Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell's life span offers a potential second route to defeat the disease--and solid tumorous cancers as well. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 18, 2020 Category: Biology Source Type: news

Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.    This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and ...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Generic Imatinib Cuts Costs Without Affecting CML Outcomes Generic Imatinib Cuts Costs Without Affecting CML Outcomes
Clinicians and their chronic myeloid leukaemia patients looking to switch to generic imatinib will see no change in outcomes or safety, while markedly reducing healthcare costs, say UK researchers.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
The FDA granted orphan drug designation to Ascentage Pharma ’s HQP1351 for the treatment of chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Finding leukemia's weakness using genome-wide CRISPR technology
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2020 Category: Cancer & Oncology Source Type: news

Researchers in Singapore find common therapeutic vulnerability for a genetically diverse and deadly
(Duke-NUS Medical School) Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2020 Category: Cancer & Oncology Source Type: news

A 66-Year-Old Man With Leukemia: USMLE Question A 66-Year-Old Man With Leukemia: USMLE Question
A 66-year-old man is found to have chronic myelogenous leukemia after a routine office visit. What is the most appropriate initial treatment in this case?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2019 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Cancer Drug Nilotinib Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news

Cancer Drug Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson's disease, a new study finds. In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news

Though safe, nilotinib does not show promise for benefit for Parkinson's disease
(Northwestern University) The Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for potential repurposing as a Parkinson's drug, was safe and tolerable in its trial population of 76 participants with moderate to advanced Parkinson's but does not exert a clinically meaningful benefit or biological effect to benefit those with Parkinson's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2019 Category: International Medicine & Public Health Source Type: news

UCLA Health partners with Kareem Abdul-Jabbar on health and wellness
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor.  The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team ca...
Source: UCLA Newsroom: Health Sciences - November 7, 2019 Category: Universities & Medical Training Source Type: news

Antibody eradicates leukemia stem cells
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.However, in most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after their cancer has gone into remission. If treatment with imatinib or another similar medication is stopped — and in some cases, even while treatment continues — the leukemia stem cells can cause cancer to recur.Now, in experiments in mice as well as isolated human cancer ...
Source: UCLA Newsroom: Health Sciences - October 15, 2019 Category: Universities & Medical Training Source Type: news

Blast Count Prognostic for CML Presenting in Advanced Phase
THURSDAY, Sept. 26, 2019 -- Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 26, 2019 Category: Pharmaceuticals Source Type: news

Leukemia drug shows promise for treating a childhood brain cancer
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego. (Source: World Pharma News)
Source: World Pharma News - September 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Chronic Myeloid Leukemia: 5 Things to Know Chronic Myeloid Leukemia: 5 Things to Know
In the wake of the tyrosine kinase inhibitor revolution, where is the treatment of CML headed?Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Promising Blood Test Could Help to Predict Breast Cancer Recurrence
Doctors have gotten much better at detecting and treating breast cancer early. Drug and chemotherapy regimens to control tumors have gotten so effective, in fact, that in some cases, surgery is no longer necessary. In up to 30% of cases of early-stage breast cancer treated before surgery, doctors can’t find evidence of cancer cells in postoperative biopsies. The problem, however, is that there is currently no reliable way to tell which cancers have been pushed into remission and which ones have not. That’s where an easy identifier, like a blood test, could transform the way early stage breast cancer is treated....
Source: TIME: Health - August 8, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized blood tests Breast Cancer Source Type: news

Chronic Leukemia | Medscape Chronic Leukemia | Medscape
Chronic leukemias -- chronic myeloid leukemia and chronic lymphocytic leukemia -- occur mostly in adults and are extremely rare in children and young persons. Chronic lymphocytic leukemia has the highest familial incidence of the leukemias. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Value of Second-Generation TKIs Must Be Considered for CML Patients
Researchers looked at second-generation tyrosine kinase inhibitors at their current prices to test treatment value for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

SIRT1 plays key role in chronic myeloid leukemia to aid persistence of leukemic stem cells
(University of Alabama at Birmingham) Patients with chronic myeloid leukemia are treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure. In a study published in the Journal of Clinical Investigation, researchers show how the stress-responsive protein SIRT1 plays important roles in maintaining the regenerative potential of CML leukemic stem cells and promoting leukemia development in CML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 10, 2019 Category: Biology Source Type: news

Diamonds Are Forever, but TKIs in CML Don't Have to Be Diamonds Are Forever, but TKIs in CML Don't Have to Be
Patients with chronic myeloid leukemia who undergo lifelong therapy with tyrosine kinase inhibitors have excellent outcomes. But treatment may not have to be forever.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Reasons for TKI Discontinuation ID'd in Chronic Myeloid Leukemia
TUESDAY, April 16, 2019 -- For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online March 16... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2019 Category: Pharmaceuticals Source Type: news

How 'sleeper cell' cancer stem cells are maintained in chronic myelogenous leukemia
(University of Alabama at Birmingham) Even when chronic myelogenous leukemia is in remission, 'sleeper cell,' quiescent leukemic stem cells are maintained in microenvironments in the bone marrow. This maintenance is poorly understood. Researchers now describe how niche-specific expression of a particular chemokine by a particular type of bone marrow cell controls quiescence of these treatment-resistant leukemic stem cells. The chemokine is CXCL12, and the particular bone marrow cells expressing it are mesenchymal stromal cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses... (Source: The Scientist)
Source: The Scientist - February 19, 2019 Category: Science Tags: The Scientist The Marketplace Source Type: news

Patients with chronic myeloid leukemia can manage their anxiety with bitter orange essential oil
(Natural News) Patients with chronic myeloid leukemia, who often suffer from anxiety, may find relief in bitter orange (Citrus aurantium L.) essential oil. A study published in the journal Phytotherapy Research reported that breathing in bitter orange essential oil could reduce anxiety in people with chronic myeloid leukemia, suggesting that it has potential use as... (Source: NaturalNews.com)
Source: NaturalNews.com - January 21, 2019 Category: Consumer Health News Source Type: news

LZTR1 is a regulator of RAS ubiquitination and signaling
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V...
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Bigenzahn, J. W., Collu, G. M., Kartnig, F., Pieraks, M., Vladimer, G. I., Heinz, L. X., Sedlyarov, V., Schischlik, F., Fauster, A., Rebsamen, M., Parapatics, K., Blomen, V. A., Müller, A. C., Winter, G. E., Kralovics, R., Brummelkamp, T. R., Mlod Tags: Cell Biology, Medicine, Diseases reports Source Type: news

Leukemic Arthritis and Severe Hypercalcemia in CML Leukemic Arthritis and Severe Hypercalcemia in CML
This case demonstrates potential manifestations of leukemic arthritis and severe hypercalcemia in patients with advanced chronic myeloid leukemia.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
CARLSBAD, Calif., Sept. 4, 2018 -- (Healthcare Sales & Marketing Network) -- Genoptix, Inc., a leading oncology diagnostic laboratory, announces the immediate availability of a proprietary, FDA-authorized BCR-ABL MRDx® TFR Monitoring Test for patients... Diagnostics, Oncology, Product Launch Genoptix, BCR-ABL MRDx, TFR Monitoring Test, chronic myeloid leukemia, Tasigna (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2018 Category: Pharmaceuticals Source Type: news

CML Following Treatment for Primary Neoplasms CML Following Treatment for Primary Neoplasms
This study aimed to characterize the clinical presentation and pathologic features of therapy-related chronic myeloid leukemia. Do they differ significantly from those of primary CML?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Payments to doctors linked to prescription practices for two cancer types
(UNC Lineberger Comprehensive Cancer Center) Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for metastatic renal cell carcinoma and for chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2018 Category: Cancer & Oncology Source Type: news

Treatment - Free Remission Feasible After Nilotinib in CML
For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second - line treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 26, 2018 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). (Source: World Pharma News)
Source: World Pharma News - December 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Pfizer ’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
December 19, 2017 -- Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Bio-Rad releases first CE-IVD digital PCR test for monitoring chronic myeloid leukemia response to therapy
(CG Life) Bio-Rad's QXDx BCR-ABL %IS Kit is the most sensitive diagnostic test available for monitoring deep molecular response of patients with chronic myeloid leukemia to tyrosine kinase inhibitor therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2017 Category: International Medicine & Public Health Source Type: news

FDA Expands Approval of Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of children... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 10, 2017 Category: Drugs & Pharmacology Source Type: news

Novartis and The Max Foundation to provide cancer access programme in lower-income countries
Novartis has entered a new collaboration with The Max Foundation to support continued access to treatment free of charge for almost 34,000 patients suffering from chronic myeloid leukaemia (CML), gastrointestinal tumours (GIST) and other rare cancers … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news

Prostaglandin EI inhibits leukemia stem cells
(University of Iowa Health Care) Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Nigeria: Leukemia Patients Celebrate 10th World CML Day
[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 22, 2017 Category: African Health Source Type: news

Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 31, 2017 Category: Intensive Care Tags: Nephrology News Source Type: news

EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news

CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Pediatric Cancers Source Type: news

New approach to leukaemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukaemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2017 Category: Biology Source Type: news

New approach to leukemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2017 Category: Cancer & Oncology Source Type: news

Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news

Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news